pharmaphorum September 22, 2025
Bayer’s much-anticipated stem cell therapy for Parkinson’s disease is gathering momentum, with dosing in phase 3 trials now underway.
The first patient has already been treated with bemdaneprocel, a one-shot treatment designed to replace the dopamine-producing neurons that degenerate in Parkinson’s, which is being developed by Bayer’s BlueRock Therapeutics subsidiary.
Meanwhile, Bayer is also making progress with a gene therapy for Parkinson’s developed by its AskBio unit, with the first European patients now entering a phase 2 trial of the AB-1005 candidate. The therapy delivers a gene into the putamen region of the brain that expresses a growth factor called GDNF, which is thought to promote the survival of dopaminergic neurons.
According to Bayer, the exPDite-2 study of bemdaneprocel is...
Today's Sponsors
Today's Sponsor